Ginkgo Bioworks Holdings (DNA) Cash from Operations (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Cash from Operations of 46433000.0 for Q1 2026, up 9.88% year-on-year from 42259615.84 in Q1 2025, and up 2.61% on a QoQ basis from 47678000.0 in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Cash from Operations data on file, last reported at 46433000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 9.88% year-over-year to 46433000.0; the trailing twelve-month figure through Mar 2026 stood at 165971000.0 (up 41.11% YoY), and the FY2025 full-year result was 171059000.0, up 46.47% from the prior year.
- Cash from Operations for Q1 2026 stood at 46433000.0, up from 47678000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 19898000.0 in Q1 2022 and bottomed at 104531000.0 in Q4 2022.
- The 5-year median for Cash from Operations is 57831000.0 (2023), against an average of 63810294.12.
- The widest annual swing landed in 2022, when Cash from Operations plunged 441.76%; it then surged 69.46% in 2025.
- A 5-year view of Cash from Operations shows it stood at 104531000.0 in 2022, then jumped by 44.68% to 57831000.0 in 2023, then advanced by 26.62% to 42435000.0 in 2024, then dropped by 12.36% to 47678000.0 in 2025, then rose by 2.61% to 46433000.0 in 2026.
- The last three Cash from Operations figures came in at 46433000.0 (Q1 2026), 47678000.0 (Q4 2025), and 31606000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | -46.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.43 Mn |
| Mar 31, 2026 | -46.43 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Sep 30, 2025 | -31.61 Mn |
| Sep 30, 2025 | -31.61 Mn |
| Jun 30, 2025 | -40.25 Mn |
| Jun 30, 2025 | -40.25 Mn |
| Mar 31, 2025 | -51.52 Mn |
| Mar 31, 2025 | -51.52 Mn |
| Dec 31, 2024 | -42.44 Mn |
| Dec 31, 2024 | -42.44 Mn |
| Sep 30, 2024 | -103.50 Mn |
| Sep 30, 2024 | -103.50 Mn |
| Jun 30, 2024 | -84.39 Mn |
| Jun 30, 2024 | -84.39 Mn |
| Mar 31, 2024 | -89.26 Mn |
| Mar 31, 2024 | -89.26 Mn |
| Dec 31, 2023 | -57.83 Mn |
| Dec 31, 2023 | -57.83 Mn |
| Sep 30, 2023 | -73.55 Mn |
| Sep 30, 2023 | -73.55 Mn |
| Jun 30, 2023 | -73.53 Mn |
| Jun 30, 2023 | -73.53 Mn |
| Mar 31, 2023 | -90.59 Mn |
| Mar 31, 2023 | -90.59 Mn |
| Dec 31, 2022 | -104.53 Mn |
| Dec 31, 2022 | -104.53 Mn |
| Sep 30, 2022 | -28.36 Mn |
| Sep 30, 2022 | -28.36 Mn |
| Jun 30, 2022 | -99.41 Mn |
| Jun 30, 2022 | -99.41 Mn |
| Mar 31, 2022 | -19.90 Mn |
| Mar 31, 2022 | -19.90 Mn |
| Dec 31, 2021 | -165.54 Mn |
| Dec 31, 2021 | -165.54 Mn |
| Sep 30, 2021 | -5.24 Mn |
| Sep 30, 2021 | -5.24 Mn |
| Jun 30, 2021 | -34.91 Mn |
| Jun 30, 2021 | -34.91 Mn |
| Mar 31, 2021 | -48.13 Mn |
| Mar 31, 2021 | -48.13 Mn |
| Dec 31, 2020 | -59.34 Mn |
| Dec 31, 2020 | -59.34 Mn |